Source: Annual Congress 2006 - Outcomes of anti-tuberculosis treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. V. Demihova, V. Y. Mishin, V. I. Chukanov, G. A. Presnova, A. N. Chistyakov (Moscow, Russian Federation). Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB. Eur Respir J 2006; 28: Suppl. 50, 165

Member's Comments

No comment yet.

Related content which might interest you: Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance Source: Eur Respir J 2006; 28: Suppl. 50, 290s Year: 2006 Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Features of intravenous anti TB therapy in patients with first diagnosed pulmonary TB in the intensive phase of treatment Source: International Congress 2017 – MDRTB: detection and management Year: 2017 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005 Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse(RTB)and newly diagnosed tuberculosis(NDTB) Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 Screening and monitoring of TB infection in rheumatological patients on biologics therapy Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs Source: Eur Respir J 2007; 30: Suppl. 51, 657s Year: 2007 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Efficacy of standard chemotherapy regimen in patients with newly detected sputum-positive destructive pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Tolerance to chemotherapy regimens with bedaquiline in adolescents with MDR/XDR pulmonary TB Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021